Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years

NCT07428759 | Active Not Recruiting Phase 1

• 1 other identifier: 300283
• Study Type: interventional
• Target: 121
• Locations: 1 country
• Sites: 2

Brief Summary

This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and will be monitored for approximately six months. The study aims to determine if PnMAPS30plus is safe and well-tolerated and whether it helps the body produce antibodies that protect against pneumococcal disease.

Conditions

Pneumonia, Bacterial

Keywords

Pn-MAPS30plus; MAPS technology; pneumococcal vaccine; Phase 1; Healthy Adults; 50-64 years

Outcome Measures

Primary Outcomes (7)

• Number of Participants with Solicited Administration Site Adverse Events (AEs)

  The solicited administration site AEs considered are pain, redness and swelling.

  Day 1 to Day 7

• Number of Participants with Solicited Systemic AEs

  The solicited systemic AEs considered are fever, headache, fatigue (tiredness), myalgia (muscle pain), and arthralgia (joint pain).

  Day 1 to Day 7

• Number of Participants with Unsolicited AEs

  An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.

  Day 1 to Day 30

• Number of Participants with Serious Adverse Events (SAEs)

  SAE is an AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or other situations that are considered serious per medical or scientific judgment.

  From Day 1 to Day 181 (study end)

• Number of Participants with Adverse Events of Special Interest (AESIs)

  From Day 1 to Day 181 (study end)

• Number of Participants with AEs Leading to withdrawal from the study

  From Day 1 to Day 181 (study end)

• Number of Participants with any Laboratory abnormalities

  Day 8 compared to Screening Visit (up to Day -14)

Study Arms (2)

Group 1: Pn- MAPS30plus

EXPERIMENTAL

Participants receive a single dose of Pn-MAPS30plus vaccine at Day 1.

Biological: Pn-MAPS30plus

Group 2: PCV20

ACTIVE COMPARATOR

Participants receive a single dose of PCV20 (20-valent pneumococcal conjugate vaccine) at Day 1.

Combination Product: PCV20

Interventions

Pn-MAPS30plus BIOLOGICAL

Single dose of Pn-MAPS30plus received intramuscularly.

Group 1: Pn- MAPS30plus

PCV20 COMBINATION_PRODUCT

Single dose of PCV20 received intramuscularly.

Group 2: PCV20

Eligibility Criteria

• Age: 50 Years - 64 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participants who, in the opinion of the investigator, can comply with the requirements (e.g., completion of the electronic diary \[eDiary\], return for follow-up visits).
• Written or witnessed/thumb printed informed consent obtained before any trial-specific procedure.
• Healthy or medically stable adults confirmed by medical history and clinical examination at screening. Participants with stable medical conditions can be enrolled at the discretion of the investigator.
• Male and female participants aged 50 and 64 years of age (YOA) at the time of Informed consent form (ICF) signature.
• Female participants of childbearing potential (POCBP) may enrol if they practice adequate contraception and have a negative pregnancy test prior to study intervention administration.

You may not qualify if:

• History of microbiologically proven invasive pneumococcal disease (IPD) caused by S. pneumoniae within 3 years before study intervention administration.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
• Any confirmed or suspected immunosuppressive or immunodeficient condition.
• Hypersensitivity to latex.
• Clinical conditions representing a contraindication to intramuscular vaccination, and blood collection.
• Documented HIV-positive status.
• Acute or unstable chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, or metabolic conditions as determined by the investigator.
• Recurrent history of uncontrolled neurological or any neuroinflammatory disorders.
• Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial.
• Any other clinical condition that, might pose additional risk to the participant.
• Use of any investigational or non-registered product other than the study interventions within 30 days before the study intervention administration.
• History of previous vaccination with any pneumococcal vaccine.
• Administration of immunoglobulins or other blood products or plasma derivatives within 90 days before or planned within 30 days after study intervention.
• Chronic administrations of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the trial.
• Pregnant or lactating female participant.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (2)

GSK Investigational Site

Norwood, South Australia, 5067, Australia

Location

GSK Investigational Site

Camberwell, Victoria, 3124, Australia

Location

MeSH Terms

Conditions

Pneumonia, Bacterial

Condition Hierarchy (Ancestors)

Bacterial Infections; Bacterial Infections and Mycoses; Infections; Pneumonia; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: This trial will be conducted in an observer-blind manner.
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 17, 2026
• First Posted: February 24, 2026
• Study Start: March 10, 2026
• Primary Completion (Estimated): December 9, 2026
• Study Completion (Estimated): December 9, 2026
• Last Updated: May 27, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
• Access Criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Locations

AU (2)